We are glad to share that we will be launching 3 more tests w.e.f. 10^th February 2025 that we will run in-house as we continue to grow and improve our service and support to our esteemed clinical partners!

As below is a summary of the new tests:

New tests w.e.f. 10th February 2025:

Some information of these 3 tests is as below:

Lipoprotein (a)

Lipoprotein (a) is a type of LDL. These lipoproteins carry cholesterol to the cells in your arteries. If you have high levels of LDL particles, cholesterol can build up in your arteries and form blockages called plaques.

Lipoprotein (a) particles are stickier than other types of LDL particles, so they may be more likely to cause blockages and blood clots in your arteries. As a result, high levels of Lipoprotein (a) may mean you have a very high risk for heart disease, stroke, and other serious conditions related to blockages and blood clots in your arteries.

Anti-Thyroid Stimulating Hormone Receptor

Hyperthyroidism in Graves’ disease (autoimmune hyperthyroidism) is typically caused by autoantibodies to the thyroid stimulating hormone receptor (TSHR), and measurement of these TSHR antibodies (TRAb) can be useful in disease diagnosis and management. The test is useful for distinguishing Graves’ disease from toxic nodular goitre, and to monitor anti-thyroid therapy and predict remission.

TSH autoantibodies can be classified as stimulating, blocking or neutral depending on their mechanism of action. Despite having actions similar to TSH, TSHR stimulating antibodies are not subject to the negative feedback mechanisms associated with TSH,

leading to prolonged activation of the TSHR. This results in the elevated thyroid hormone levels and clinical thyrotoxic state associated with Graves’ disease.

Indications for TRAb determination include:

• The presence of TRAb indicates that the patient’s thyrotoxicosis is of autoimmune aetiology rather than due to toxic nodular goiter. Because the aim of treatment for Graves’ disease may differ from the treatment of other forms of thyrotoxicosis.
• Monitoring the therapy of Graves’ disease patients and prediction of relapse, thereby constituting an important decision-making aid in treatment management.
• TRAb measurement during the last trimester of pregnancy. Because TRAb are IgG‑class antibodies, they cross the placenta and can cause neonatal thyroid disease. The measurement of TRAb during pregnancy in patients with a history of thyroid disease is therefore important in assessing the risk of thyroid disease in the neonate

Anti-Müllerian Hormone

The anti‑Müllerian hormone is a homodimeric glycoprotein belonging to the transforming growth factor β (TGF β) family. All members of this superfamily are involved in the regulation of tissue growth and differentiation. The AMH test is a valuable tool in assessing a woman’s reproductive potential. Here’s what it can tell you:

Ovarian reserve

• AMH levels provide an estimate of the number of eggs remaining in a woman’s ovaries. This is known as the ovarian reserve.

Fertility potential

• Higher AMH levels generally suggest a greater number of eggs and potentially better fertility prospects. Lower levels may indicate a diminished ovarian reserve.

Response to fertility treatments

• AMH levels can help predict how well a woman might respond to assisted reproductive technologies such as in vitro fertilisation (IVF).

Reproductive lifespan

• The test can offer insights into a woman’s reproductive lifespan, though it cannot predict the exact age of menopause.

PCOS indication

• Unusually high AMH levels may suggest polycystic ovary syndrome (PCOS), a common cause of infertility.

• Share